Recurrence score prediction formula based on immunohistochemistry and biopsy data to predict response to neoadjuvant chemotherapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer
Oncotype DX® is a validated 21-gene tool for assessing survival benefits of adjuvant chemotherapy for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer, but its use in core biopsy specimens is limited by costs, access issues, and available tissue volumes, highlight...